The Manufacturers Life Insurance Company Purchases New Position in Zura Bio Limited (NASDAQ:ZURA)

The Manufacturers Life Insurance Company acquired a new position in Zura Bio Limited (NASDAQ:ZURA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,442 shares of the company’s stock, valued at approximately $71,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asset Management L.P. acquired a new position in shares of Zura Bio in the 2nd quarter valued at $8,446,000. Armistice Capital LLC grew its position in Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after buying an additional 876,000 shares during the period. Great Point Partners LLC increased its holdings in Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after buying an additional 1,884,501 shares in the last quarter. Forefront Analytics LLC raised its position in shares of Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after acquiring an additional 7,531 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Zura Bio during the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Insider Transactions at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 22.10% of the company’s stock.

Zura Bio Price Performance

Shares of Zura Bio stock opened at $2.51 on Wednesday. The business has a 50 day simple moving average of $3.69 and a two-hundred day simple moving average of $3.74. Zura Bio Limited has a 12 month low of $2.00 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, research analysts predict that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital cut their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research note on Monday, November 18th. Finally, Leerink Partners started coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.80.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.